📊 LQDA Key Takeaways
Is Liquidia Corp (LQDA) a Good Investment?
Liquidia demonstrates extraordinary revenue growth of 1031% YoY, suggesting successful product launch or acquisition integration, but remains deeply unprofitable with -32.5% operating margin and -$40M annual free cash flow burn. Despite a strong $190.7M cash position and low debt, the company's failure to convert explosive growth into profitability, combined with high insider trading activity, indicates execution risk in a competitive pharmaceutical market.
Liquidia exhibits a major revenue inflection and a strong cash position that can support commercialization and pipeline execution. However, profitability remains weak with sizable operating losses and negative free cash flow, and the quality/sustainability of growth is uncertain given missing gross margin detail and potential one-time revenue.
Why Buy Liquidia Corp Stock? LQDA Key Strengths
- Exceptional revenue growth of 1031% YoY demonstrating successful market penetration or transformative acquisition
- Fortress balance sheet with $190.7M cash, minimal long-term debt of $19.9M, and 2.01x current ratio
- Sufficient cash runway exceeding 5 years at current burn rate providing time for profitability inflection
- Rapid revenue growth to $158.3M (+1031% YoY)
- Strong liquidity with $190.7M cash and 2.0x current ratio
- Low long-term debt and moderate leverage (Debt/Equity 0.44x)
LQDA Stock Risks: Liquidia Corp Investment Risks
- Severe profitability deficit with negative operating margin (-32.5%) and persistent cash burn (-$40M annually) despite revenue scale
- Pharmaceutical sector regulatory and competitive pressures with unclear margin expansion pathway despite growth achievement
- Abnormally high insider trading activity (32 Form 4 filings in 90 days) potentially signaling insider concerns about business trajectory
- Operating cash flow deterioration (-$35.7M) despite 1031% growth suggests unsustainable cost structure or acquisition integration challenges
- Persistent losses and negative margins (operating -32.5%, net -43.5%)
- Negative operating and free cash flow implying ongoing burn
- Growth quality unclear (no gross margin; potential one-off revenue; low equity vs liabilities)
Key Metrics to Watch
- Operating margin trajectory and timeline to breakeven profitability with sustained revenue growth
- Operating cash flow inflection point and path to positive free cash flow generation
- Gross margin sustainability and operating expense leverage as revenue scales
- Cash burn rate deceleration and working capital efficiency in next two quarters
- Recurring product revenue (vs. one-time/licensing)
- Operating cash flow and burn rate
Liquidia Corp (LQDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.01x current ratio provides a solid financial cushion.
LQDA Profit Margin, ROE & Profitability Analysis
LQDA vs Healthcare Sector: How Liquidia Corp Compares
How Liquidia Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Liquidia Corp Stock Overvalued? LQDA Valuation Analysis 2026
Based on fundamental analysis, Liquidia Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Liquidia Corp Balance Sheet: LQDA Debt, Cash & Liquidity
LQDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Liquidia Corp's revenue has grown significantly by 1,132% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
LQDA Revenue Growth, EPS Growth & YoY Performance
LQDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.4M | -$3.5M | $-0.04 |
| Q2 2025 | $3.7M | -$28.7M | $-0.38 |
| Q1 2025 | $3.0M | -$30.1M | $-0.40 |
| Q3 2024 | $3.7M | -$11.7M | $-0.24 |
| Q2 2024 | $3.7M | -$11.7M | $-0.36 |
| Q1 2024 | $3.0M | -$11.7M | $-0.18 |
| Q3 2023 | $3.2M | -$9.1M | $-0.14 |
| Q2 2023 | $3.9M | -$9.4M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Liquidia Corp Dividends, Buybacks & Capital Allocation
LQDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Liquidia Corp (CIK: 0001819576)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 14, 2026 | 4 | xslF345X06/tm2611789-8_4seq1.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/tm2611789-7_4seq1.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/tm2611789-6_4seq1.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/tm2611789-5_4seq1.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/tm2611789-4_4seq1.xml | View → |
❓ Frequently Asked Questions about LQDA
What is the AI rating for LQDA?
Liquidia Corp (LQDA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LQDA's key strengths?
Claude: Exceptional revenue growth of 1031% YoY demonstrating successful market penetration or transformative acquisition. Fortress balance sheet with $190.7M cash, minimal long-term debt of $19.9M, and 2.01x current ratio. ChatGPT: Rapid revenue growth to $158.3M (+1031% YoY). Strong liquidity with $190.7M cash and 2.0x current ratio.
What are the risks of investing in LQDA?
Claude: Severe profitability deficit with negative operating margin (-32.5%) and persistent cash burn (-$40M annually) despite revenue scale. Pharmaceutical sector regulatory and competitive pressures with unclear margin expansion pathway despite growth achievement. ChatGPT: Persistent losses and negative margins (operating -32.5%, net -43.5%). Negative operating and free cash flow implying ongoing burn.
What is LQDA's revenue and growth?
Liquidia Corp reported revenue of $158.3M.
Does LQDA pay dividends?
Liquidia Corp does not currently pay dividends.
Where can I find LQDA SEC filings?
Official SEC filings for Liquidia Corp (CIK: 0001819576) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LQDA's EPS?
Liquidia Corp has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LQDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Liquidia Corp has a SELL rating with 66% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LQDA stock overvalued or undervalued?
Valuation metrics for LQDA: ROE of -154.0% (sector avg: 15%), net margin of -43.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LQDA stock in 2026?
Our dual AI analysis gives Liquidia Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LQDA's free cash flow?
Liquidia Corp's operating cash flow is $-35.7M, with capital expenditures of $4.3M. FCF margin is -25.3%.
How does LQDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -43.5% (avg: 12%), ROE -154.0% (avg: 15%), current ratio 2.01 (avg: 2).